WALTHAM, Mass. — BostonGene announced that seven of its research abstracts have been selected for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9–12 in San Antonio, Texas. The studies, developed in collaboration with major cancer centers, highlight the company’s AI and omnimodal profiling technology and its ability to decode tumor biology, identify predictive immune signatures and uncover new therapeutic targets. BostonGene will also exhibit at booth 1352.
The presentations underscore how BostonGene’s platform integrates genomic, transcriptomic, proteomic and immune system data to advance personalized treatment strategies for breast cancer.
One study, led by clinicians at The University of Texas MD Anderson Cancer Center, profiled peripheral blood from patients with high-risk, early-stage triple-negative breast cancer (TNBC) receiving the KEYNOTE-522 regimen. Scheduled for a poster spotlight discussion on December 11, the research used BostonGene’s immune phenotyping platform and AI-driven immunotype signatures to identify circulating immune cells associated with improved pathological response. Investigators said the findings point to promising minimally invasive biomarkers that may help identify patients most likely to benefit from immune-based neoadjuvant therapy.
A second poster spotlight, presented by a Dana-Farber Cancer Institute researcher, evaluated the feasibility of BostonGene’s machine learning–based immunoprofiling technology in patients with early-stage TNBC. The study compared immune profile differences between chemotherapy alone and chemo-immunotherapy, tracking how immunotypes evolved across treatment. Researchers found meaningful variation in immune responses based on therapy type and noted dynamic changes in patients receiving combined treatment. According to the team, these results demonstrate the potential for peripheral blood immune monitoring to refine patient stratification, guide trial design and inform treatment optimization.
Both studies reflect collaborations with MD Anderson Cancer Center and Brigham and Women’s Hospital. Additional BostonGene research accepted for SABCS will further explore tumor microenvironment profiling, response prediction and novel therapeutic pathways in breast cancer.
